Annual Current Liabilities
$110.31 M
+$18.82 M+20.57%
December 31, 2023
Summary
- As of February 7, 2025, IOVA annual total current liabilities is $110.31 million, with the most recent change of +$18.82 million (+20.57%) on December 31, 2023.
- During the last 3 years, IOVA annual current liabilities has risen by +$55.44 million (+101.03%).
- IOVA annual current liabilities is now at all-time high.
Performance
IOVA Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$118.06 M
+$24.42 M+26.08%
September 30, 2024
Summary
- As of February 7, 2025, IOVA quarterly total current liabilities is $118.06 million, with the most recent change of +$24.42 million (+26.08%) on September 30, 2024.
- Over the past year, IOVA quarterly current liabilities has increased by +$34.84 million (+41.87%).
- IOVA quarterly current liabilities is now at all-time high.
Performance
IOVA Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
IOVA Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +20.6% | +41.9% |
| 3 y3 years | +101.0% | +83.9% |
| 5 y5 years | +666.1% | +83.9% |
IOVA Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +23.7% | at high | +83.9% |
| 5 y | 5-year | at high | +182.2% | at high | +202.1% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Iovance Biotherapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $118.06 M(+26.1%) |
| Jun 2024 | - | $93.64 M(+12.5%) |
| Mar 2024 | - | $83.21 M(-24.6%) |
| Dec 2023 | $110.31 M(+20.6%) | $110.31 M(+21.3%) |
| Sep 2023 | - | $90.95 M(+2.6%) |
| Jun 2023 | - | $88.64 M(+1.6%) |
| Mar 2023 | - | $87.27 M(-4.6%) |
| Dec 2022 | $91.48 M(+2.6%) | $91.48 M(+15.4%) |
| Sep 2022 | - | $79.25 M(+23.4%) |
| Jun 2022 | - | $64.19 M(-16.7%) |
| Mar 2022 | - | $77.08 M(-13.6%) |
| Dec 2021 | $89.20 M(+62.6%) | $89.20 M(+37.7%) |
| Sep 2021 | - | $64.77 M(+7.0%) |
| Jun 2021 | - | $60.53 M(+9.9%) |
| Mar 2021 | - | $55.06 M(+0.3%) |
| Dec 2020 | $54.87 M(+40.4%) | $54.87 M(-14.8%) |
| Sep 2020 | - | $64.39 M(+17.3%) |
| Jun 2020 | - | $54.91 M(+38.8%) |
| Mar 2020 | - | $39.55 M(+1.2%) |
| Dec 2019 | $39.08 M(+171.5%) | $39.08 M(+12.9%) |
| Sep 2019 | - | $34.61 M(+2.3%) |
| Jun 2019 | - | $33.84 M(+52.8%) |
| Mar 2019 | - | $22.14 M(+53.8%) |
| Dec 2018 | $14.40 M(+50.1%) | $14.40 M(-13.6%) |
| Sep 2018 | - | $16.67 M(+17.6%) |
| Jun 2018 | - | $14.18 M(-3.5%) |
| Mar 2018 | - | $14.69 M(+53.1%) |
| Dec 2017 | $9.60 M(+93.1%) | $9.60 M(+12.5%) |
| Sep 2017 | - | $8.53 M(-3.7%) |
| Jun 2017 | - | $8.86 M(+61.0%) |
| Mar 2017 | - | $5.50 M(+10.8%) |
| Dec 2016 | $4.97 M | $4.97 M(+55.5%) |
| Sep 2016 | - | $3.19 M(-30.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2016 | - | $4.61 M(+151.7%) |
| Mar 2016 | - | $1.83 M(+12.3%) |
| Dec 2015 | $1.63 M(-1.9%) | $1.63 M(-42.9%) |
| Sep 2015 | - | $2.85 M(+53.0%) |
| Jun 2015 | - | $1.87 M(-2.3%) |
| Mar 2015 | - | $1.91 M(+15.0%) |
| Dec 2014 | $1.66 M(-26.8%) | $1.66 M(+32.0%) |
| Sep 2014 | - | $1.26 M(+8.8%) |
| Jun 2014 | - | $1.16 M(+4.2%) |
| Mar 2014 | - | $1.11 M(-51.1%) |
| Dec 2013 | $2.27 M(-80.0%) | $2.27 M(-35.3%) |
| Sep 2013 | - | $3.51 M(+4.2%) |
| Jun 2013 | - | $3.37 M(-72.6%) |
| Mar 2013 | - | $12.31 M(+8.4%) |
| Dec 2012 | $11.35 M(-15.0%) | $11.35 M(-31.7%) |
| Sep 2012 | - | $16.61 M(-0.4%) |
| Jun 2012 | - | $16.68 M(-3.8%) |
| Mar 2012 | - | $17.34 M(+29.9%) |
| Dec 2011 | $13.35 M(+1522.2%) | $13.35 M(+46.2%) |
| Sep 2011 | - | $9.13 M(+388.2%) |
| Jun 2011 | - | $1.87 M(+142.5%) |
| Mar 2011 | - | $771.10 K(-6.3%) |
| Dec 2010 | $822.90 K(+3462.3%) | $822.90 K(+43.8%) |
| Sep 2010 | - | $572.20 K(+3521.5%) |
| Jun 2010 | - | $15.80 K(-55.1%) |
| Mar 2010 | - | $35.20 K(+52.4%) |
| Dec 2009 | $23.10 K(+600.0%) | $23.10 K(+69.9%) |
| Sep 2009 | - | $13.60 K(+23.6%) |
| Jun 2009 | - | $11.00 K(+32.5%) |
| Mar 2009 | - | $8300.00(+151.5%) |
| Dec 2008 | $3300.00 | $3300.00(+3.1%) |
| Sep 2008 | - | $3200.00(+60.0%) |
| Jun 2008 | - | $2000.00(+11.1%) |
| Mar 2008 | - | $1800.00 |
FAQ
- What is Iovance Biotherapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual current liabilities year-on-year change?
- What is Iovance Biotherapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly current liabilities year-on-year change?
What is Iovance Biotherapeutics annual total current liabilities?
The current annual current liabilities of IOVA is $110.31 M
What is the all time high annual current liabilities for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual total current liabilities is $110.31 M
What is Iovance Biotherapeutics annual current liabilities year-on-year change?
Over the past year, IOVA annual total current liabilities has changed by +$18.82 M (+20.57%)
What is Iovance Biotherapeutics quarterly total current liabilities?
The current quarterly current liabilities of IOVA is $118.06 M
What is the all time high quarterly current liabilities for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly total current liabilities is $118.06 M
What is Iovance Biotherapeutics quarterly current liabilities year-on-year change?
Over the past year, IOVA quarterly total current liabilities has changed by +$34.84 M (+41.87%)